Cargando…

Vacuum-assisted biopsy system for breast lesions: a potential therapeutic approach

PURPOSE: The primary objective is to optimize the population eligible for Mammotome Minimally Invasive Surgery (MIS) by refining selection criteria. This involves maximizing procedure benefits, minimizing malignancy risk, and reducing the rate of malignant outcomes. PATIENTS AND METHODS: A total of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yue, Chen, Xingyan, Dou, He, Liu, Yuqi, Li, Fucheng, Wang, Youyu, Xiao, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430071/
https://www.ncbi.nlm.nih.gov/pubmed/37593094
http://dx.doi.org/10.3389/fonc.2023.1230083
_version_ 1785090866157715456
author Zhu, Yue
Chen, Xingyan
Dou, He
Liu, Yuqi
Li, Fucheng
Wang, Youyu
Xiao, Min
author_facet Zhu, Yue
Chen, Xingyan
Dou, He
Liu, Yuqi
Li, Fucheng
Wang, Youyu
Xiao, Min
author_sort Zhu, Yue
collection PubMed
description PURPOSE: The primary objective is to optimize the population eligible for Mammotome Minimally Invasive Surgery (MIS) by refining selection criteria. This involves maximizing procedure benefits, minimizing malignancy risk, and reducing the rate of malignant outcomes. PATIENTS AND METHODS: A total of 1158 female patients who came to our hospital from November 2016 to August 2021 for the Mammotome MIS were analyzed retrospectively. Following χ2 tests to screen for risk variables, binary logistic regression analysis was used to determine the independent predictors of malignant lesions. In addition, the correlation between age and lesion diameter was investigated for BI-RADS ultrasound (US) category 4a lesions in order to better understand the relationship between these variables. RESULTS: The malignancy rates of BI-RADS US category 3, category 4a and category 4b patients who underwent the Mammotome MIS were 0.6% (9/1562), 6.4% (37/578) and 8.3% (2/24) respectively. Malignant lesions were more common in patients over the age of 40, have visible blood supply, and BI-RADS category 4 of mammography. In BI-RADS US category 4a lesions, the diameter of malignant tumor was highly correlated with age, and this correlation was strengthened in patients over the age of 40 and with BI-RADS category 4 of mammography. CONCLUSION: The results of this study demonstrate that the clinical data and imaging results, particularly age, blood supply, and mammography classification, offer valuable insights to optimize patients’ surgical options and decrease the incidence of malignant outcomes.
format Online
Article
Text
id pubmed-10430071
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104300712023-08-17 Vacuum-assisted biopsy system for breast lesions: a potential therapeutic approach Zhu, Yue Chen, Xingyan Dou, He Liu, Yuqi Li, Fucheng Wang, Youyu Xiao, Min Front Oncol Oncology PURPOSE: The primary objective is to optimize the population eligible for Mammotome Minimally Invasive Surgery (MIS) by refining selection criteria. This involves maximizing procedure benefits, minimizing malignancy risk, and reducing the rate of malignant outcomes. PATIENTS AND METHODS: A total of 1158 female patients who came to our hospital from November 2016 to August 2021 for the Mammotome MIS were analyzed retrospectively. Following χ2 tests to screen for risk variables, binary logistic regression analysis was used to determine the independent predictors of malignant lesions. In addition, the correlation between age and lesion diameter was investigated for BI-RADS ultrasound (US) category 4a lesions in order to better understand the relationship between these variables. RESULTS: The malignancy rates of BI-RADS US category 3, category 4a and category 4b patients who underwent the Mammotome MIS were 0.6% (9/1562), 6.4% (37/578) and 8.3% (2/24) respectively. Malignant lesions were more common in patients over the age of 40, have visible blood supply, and BI-RADS category 4 of mammography. In BI-RADS US category 4a lesions, the diameter of malignant tumor was highly correlated with age, and this correlation was strengthened in patients over the age of 40 and with BI-RADS category 4 of mammography. CONCLUSION: The results of this study demonstrate that the clinical data and imaging results, particularly age, blood supply, and mammography classification, offer valuable insights to optimize patients’ surgical options and decrease the incidence of malignant outcomes. Frontiers Media S.A. 2023-08-01 /pmc/articles/PMC10430071/ /pubmed/37593094 http://dx.doi.org/10.3389/fonc.2023.1230083 Text en Copyright © 2023 Zhu, Chen, Dou, Liu, Li, Wang and Xiao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhu, Yue
Chen, Xingyan
Dou, He
Liu, Yuqi
Li, Fucheng
Wang, Youyu
Xiao, Min
Vacuum-assisted biopsy system for breast lesions: a potential therapeutic approach
title Vacuum-assisted biopsy system for breast lesions: a potential therapeutic approach
title_full Vacuum-assisted biopsy system for breast lesions: a potential therapeutic approach
title_fullStr Vacuum-assisted biopsy system for breast lesions: a potential therapeutic approach
title_full_unstemmed Vacuum-assisted biopsy system for breast lesions: a potential therapeutic approach
title_short Vacuum-assisted biopsy system for breast lesions: a potential therapeutic approach
title_sort vacuum-assisted biopsy system for breast lesions: a potential therapeutic approach
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430071/
https://www.ncbi.nlm.nih.gov/pubmed/37593094
http://dx.doi.org/10.3389/fonc.2023.1230083
work_keys_str_mv AT zhuyue vacuumassistedbiopsysystemforbreastlesionsapotentialtherapeuticapproach
AT chenxingyan vacuumassistedbiopsysystemforbreastlesionsapotentialtherapeuticapproach
AT douhe vacuumassistedbiopsysystemforbreastlesionsapotentialtherapeuticapproach
AT liuyuqi vacuumassistedbiopsysystemforbreastlesionsapotentialtherapeuticapproach
AT lifucheng vacuumassistedbiopsysystemforbreastlesionsapotentialtherapeuticapproach
AT wangyouyu vacuumassistedbiopsysystemforbreastlesionsapotentialtherapeuticapproach
AT xiaomin vacuumassistedbiopsysystemforbreastlesionsapotentialtherapeuticapproach